Benchling, a San Francisco, CA-based data management and collaboration platform built to advance life sciences research, closed $14.5M in Series B funding.
The round was led by Benchmark, with participation from F-Prime Capital, a global venture capital firm associated with Fidelity Investments, and returning investor Thrive Capital. In conjunction with the funding, Benchmark General Partner Eric Vishria will be joining the board of directors.
The company intends to use the funds to accelerate product development, continue growing its team, focus on growing its customer base.
Led by co-founder and CEO Sajith Wickramasekara, Benchling empowers R&D teams with a suite of unified applications to encourage active collaboration, design and track biologics research, and accelerate the production and retention of knowledge.
Today, more than 100,000 scientists across enterprises and academia are using Benchling.
The customer base includes enterprise companies and some of the world’s most renowned research labs at universities such as Harvard, MIT, UC Berkeley, and Stanford.